Masimo Corporation (NASDAQ: MASI) Stock Competitors & Peer Comparison
See MASI's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for MASI and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MASI | $179.95 | +0.00% | 9.4B | 44.43 | $4.05 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $100.98 | -0.31% | 174.7B | 19.38 | $5.21 | +2.45% |
| MDT | $89.50 | +0.97% | 114.5B | 16.18 | $5.53 | +3.24% |
| SYK | $275.31 | +1.08% | 105.6B | 20.57 | $13.39 | +1.28% |
| BSX | $44.11 | +0.43% | 65.6B | 14.23 | $3.10 | N/A |
| EW | $86.83 | +0.63% | 50B | 32.16 | $2.70 | N/A |
| DXCM | $86.68 | +0.07% | 32.7B | 33.99 | $2.55 | N/A |
| GEHC | $66.78 | +0.23% | 30.2B | 14.64 | $4.56 | +0.21% |
| PHG | $25.11 | +0.60% | 24.5B | 14.35 | $1.75 | +3.97% |
Stock Comparison
Boston Scientific Corporation (NYSE: BSX-PA)
MASI vs BSX-PA Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, MASI's ROE is +0.09%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, MASI is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for MASI.Check BSX-PA's competition here
Abbott Laboratories (NYSE: ABT)
MASI vs ABT Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, ABT has a market cap of 174.7B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while ABT trades at $100.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas ABT's P/E ratio is 19.38. In terms of profitability, MASI's ROE is +0.09%, compared to ABT's ROE of +0.11%. Regarding short-term risk, MASI is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for MASI.Check ABT's competition here
Medtronic plc (NYSE: MDT)
MASI vs MDT Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, MDT has a market cap of 114.5B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while MDT trades at $89.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas MDT's P/E ratio is 16.18. In terms of profitability, MASI's ROE is +0.09%, compared to MDT's ROE of +0.11%. Regarding short-term risk, MASI is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for MASI.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
MASI vs SYK Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, SYK has a market cap of 105.6B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while SYK trades at $275.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas SYK's P/E ratio is 20.57. In terms of profitability, MASI's ROE is +0.09%, compared to SYK's ROE of +0.16%. Regarding short-term risk, MASI is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for MASI.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
MASI vs BSX Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, BSX has a market cap of 65.6B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while BSX trades at $44.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas BSX's P/E ratio is 14.23. In terms of profitability, MASI's ROE is +0.09%, compared to BSX's ROE of +0.15%. Regarding short-term risk, MASI is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for MASI.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
MASI vs EW Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, EW has a market cap of 50B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while EW trades at $86.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas EW's P/E ratio is 32.16. In terms of profitability, MASI's ROE is +0.09%, compared to EW's ROE of +0.10%. Regarding short-term risk, MASI is less volatile compared to EW. This indicates lower risk in terms of short-term price fluctuations for MASI.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
MASI vs DXCM Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, DXCM has a market cap of 32.7B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while DXCM trades at $86.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas DXCM's P/E ratio is 33.99. In terms of profitability, MASI's ROE is +0.09%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, MASI is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for MASI.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
MASI vs GEHC Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, GEHC has a market cap of 30.2B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while GEHC trades at $66.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas GEHC's P/E ratio is 14.64. In terms of profitability, MASI's ROE is +0.09%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, MASI is less volatile compared to GEHC. This indicates lower risk in terms of short-term price fluctuations for MASI.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
MASI vs PHG Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, PHG has a market cap of 24.5B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while PHG trades at $25.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas PHG's P/E ratio is 14.35. In terms of profitability, MASI's ROE is +0.09%, compared to PHG's ROE of +0.10%. Regarding short-term risk, MASI is less volatile compared to PHG. This indicates lower risk in terms of short-term price fluctuations for MASI.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
MASI vs ZBH Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, ZBH has a market cap of 17.7B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while ZBH trades at $91.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas ZBH's P/E ratio is 10.80. In terms of profitability, MASI's ROE is +0.09%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, MASI is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for MASI.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
MASI vs ABMD Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas ABMD's P/E ratio is 65.36. In terms of profitability, MASI's ROE is +0.09%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, MASI is less volatile compared to ABMD. This indicates lower risk in terms of short-term price fluctuations for MASI.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
MASI vs PEN Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while PEN trades at $319.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas PEN's P/E ratio is 83.31. In terms of profitability, MASI's ROE is +0.09%, compared to PEN's ROE of +0.11%. Regarding short-term risk, MASI is less volatile compared to PEN. This indicates lower risk in terms of short-term price fluctuations for MASI.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
MASI vs SWAV Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas SWAV's P/E ratio is 78.76. In terms of profitability, MASI's ROE is +0.09%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, MASI is less volatile compared to SWAV. This indicates lower risk in terms of short-term price fluctuations for MASI.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
MASI vs SNN Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, SNN has a market cap of 11.4B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while SNN trades at $27.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas SNN's P/E ratio is 18.28. In terms of profitability, MASI's ROE is +0.09%, compared to SNN's ROE of +0.12%. Regarding short-term risk, MASI is less volatile compared to SNN. This indicates lower risk in terms of short-term price fluctuations for MASI.Check SNN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
MASI vs BIO-B Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, BIO-B has a market cap of 10.5B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while BIO-B trades at $385.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas BIO-B's P/E ratio is -67.89. In terms of profitability, MASI's ROE is +0.09%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, MASI is similarly volatile compared to BIO-B. This indicates similar risk in terms of short-term price fluctuations for MASI.Check BIO-B's competition here
Align Technology, Inc. (NASDAQ: ALGN)
MASI vs ALGN Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, ALGN has a market cap of 10.4B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while ALGN trades at $145.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas ALGN's P/E ratio is 13.22. In terms of profitability, MASI's ROE is +0.09%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, MASI is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for MASI.Check ALGN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
MASI vs BIO Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, BIO has a market cap of 10.2B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while BIO trades at $377.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas BIO's P/E ratio is 40.70. In terms of profitability, MASI's ROE is +0.09%, compared to BIO's ROE of +0.03%. Regarding short-term risk, MASI is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for MASI.Check BIO's competition here
Globus Medical, Inc. (NYSE: GMED)
MASI vs GMED Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, GMED has a market cap of 10.1B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while GMED trades at $74.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas GMED's P/E ratio is 16.84. In terms of profitability, MASI's ROE is +0.09%, compared to GMED's ROE of +0.12%. Regarding short-term risk, MASI is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for MASI.Check GMED's competition here
Bruker Corporation (NASDAQ: BRKR)
MASI vs BRKR Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, BRKR has a market cap of 9.6B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while BRKR trades at $63.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas BRKR's P/E ratio is 31.80. In terms of profitability, MASI's ROE is +0.09%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, MASI is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for MASI.Check BRKR's competition here
Glaukos Corporation (NYSE: GKOS)
MASI vs GKOS Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, GKOS has a market cap of 9.3B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while GKOS trades at $158.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas GKOS's P/E ratio is -184.31. In terms of profitability, MASI's ROE is +0.09%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, MASI is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for MASI.Check GKOS's competition here
Bruker Corporation (NASDAQ: BRKRP)
MASI vs BRKRP Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, BRKRP has a market cap of 9.3B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while BRKRP trades at $469.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas BRKRP's P/E ratio is 251.76. In terms of profitability, MASI's ROE is +0.09%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, MASI is less volatile compared to BRKRP. This indicates lower risk in terms of short-term price fluctuations for MASI.Check BRKRP's competition here
Insulet Corp. (NASDAQ: PODD)
MASI vs PODD Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, PODD has a market cap of 9.2B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while PODD trades at $133.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas PODD's P/E ratio is 22.68. In terms of profitability, MASI's ROE is +0.09%, compared to PODD's ROE of +0.27%. Regarding short-term risk, MASI is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for MASI.Check PODD's competition here
Haemonetics Corporation (NYSE: HAE)
MASI vs HAE Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, HAE has a market cap of 4.8B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while HAE trades at $105.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas HAE's P/E ratio is 21.13. In terms of profitability, MASI's ROE is +0.09%, compared to HAE's ROE of +0.11%. Regarding short-term risk, MASI is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for MASI.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
MASI vs NARI Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas NARI's P/E ratio is -59.24. In terms of profitability, MASI's ROE is +0.09%, compared to NARI's ROE of -0.00%. Regarding short-term risk, MASI is less volatile compared to NARI. This indicates lower risk in terms of short-term price fluctuations for MASI.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
MASI vs ITGR Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while ITGR trades at $126.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas ITGR's P/E ratio is 19.90. In terms of profitability, MASI's ROE is +0.09%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, MASI is less volatile compared to ITGR. This indicates lower risk in terms of short-term price fluctuations for MASI.Check ITGR's competition here
LivaNova PLC (NASDAQ: LIVN)
MASI vs LIVN Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while LIVN trades at $77.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas LIVN's P/E ratio is 18.34. In terms of profitability, MASI's ROE is +0.09%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, MASI is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for MASI.Check LIVN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
MASI vs IRTC Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, IRTC has a market cap of 3.7B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while IRTC trades at $112.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas IRTC's P/E ratio is -261.86. In terms of profitability, MASI's ROE is +0.09%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, MASI is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for MASI.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
MASI vs AXNX Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas AXNX's P/E ratio is -709.80. In terms of profitability, MASI's ROE is +0.09%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, MASI is similarly volatile compared to AXNX. This indicates similar risk in terms of short-term price fluctuations for MASI.Check AXNX's competition here
Neogen Corporation (NASDAQ: NEOG)
MASI vs NEOG Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, NEOG has a market cap of 3B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while NEOG trades at $13.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas NEOG's P/E ratio is 49.00. In terms of profitability, MASI's ROE is +0.09%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, MASI is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for MASI.Check NEOG's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
MASI vs TMDX Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while TMDX trades at $82.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas TMDX's P/E ratio is 41.99. In terms of profitability, MASI's ROE is +0.09%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, MASI is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for MASI.Check TMDX's competition here
Butterfly Network, Inc. (NYSE: BFLY)
MASI vs BFLY Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, BFLY has a market cap of 2.4B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while BFLY trades at $9.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas BFLY's P/E ratio is -38.10. In terms of profitability, MASI's ROE is +0.09%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, MASI is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for MASI.Check BFLY's competition here
AxoGen, Inc. (NASDAQ: AXGN)
MASI vs AXGN Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while AXGN trades at $43.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas AXGN's P/E ratio is 114.11. In terms of profitability, MASI's ROE is +0.09%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, MASI is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for MASI.Check AXGN's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
MASI vs UFPT Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while UFPT trades at $299.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas UFPT's P/E ratio is 30.56. In terms of profitability, MASI's ROE is +0.09%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, MASI is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for MASI.Check UFPT's competition here
NuVasive, Inc. (NASDAQ: NUVA)
MASI vs NUVA Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas NUVA's P/E ratio is 75.00. In terms of profitability, MASI's ROE is +0.09%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, MASI is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for MASI.Check NUVA's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
MASI vs INSP Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, INSP has a market cap of 2B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while INSP trades at $70.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas INSP's P/E ratio is 30.84. In terms of profitability, MASI's ROE is +0.09%, compared to INSP's ROE of +0.18%. Regarding short-term risk, MASI is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for MASI.Check INSP's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
MASI vs ESTA Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while ESTA trades at $65.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas ESTA's P/E ratio is -51.86. In terms of profitability, MASI's ROE is +0.09%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, MASI is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for MASI.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
MASI vs NVCR Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while NVCR trades at $15.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas NVCR's P/E ratio is -12.18. In terms of profitability, MASI's ROE is +0.09%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, MASI is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for MASI.Check NVCR's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
MASI vs ATEC Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while ATEC trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas ATEC's P/E ratio is -167.50. In terms of profitability, MASI's ROE is +0.09%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, MASI is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for MASI.Check ATEC's competition here
CONMED Corporation (NYSE: CNMD)
MASI vs CNMD Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while CNMD trades at $46.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas CNMD's P/E ratio is 10.20. In terms of profitability, MASI's ROE is +0.09%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, MASI is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for MASI.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
MASI vs HSKA Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas HSKA's P/E ratio is -62.49. In terms of profitability, MASI's ROE is +0.09%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, MASI is similarly volatile compared to HSKA. This indicates similar risk in terms of short-term price fluctuations for MASI.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
MASI vs IART Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while IART trades at $16.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas IART's P/E ratio is 6.89. In terms of profitability, MASI's ROE is +0.09%, compared to IART's ROE of -0.01%. Regarding short-term risk, MASI is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for MASI.Check IART's competition here
Avanos Medical, Inc. (NYSE: AVNS)
MASI vs AVNS Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas AVNS's P/E ratio is 27.77. In terms of profitability, MASI's ROE is +0.09%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, MASI is less volatile compared to AVNS. This indicates lower risk in terms of short-term price fluctuations for MASI.Check AVNS's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
MASI vs TNDM Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while TNDM trades at $16.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas TNDM's P/E ratio is -17.66. In terms of profitability, MASI's ROE is +0.09%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, MASI is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for MASI.Check TNDM's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
MASI vs SILK Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas SILK's P/E ratio is -18.96. In terms of profitability, MASI's ROE is +0.09%, compared to SILK's ROE of -0.35%. Regarding short-term risk, MASI is less volatile compared to SILK. This indicates lower risk in terms of short-term price fluctuations for MASI.Check SILK's competition here
Artivion, Inc. (NYSE: AORT)
MASI vs AORT Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while AORT trades at $22.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas AORT's P/E ratio is 38.23. In terms of profitability, MASI's ROE is +0.09%, compared to AORT's ROE of -0.01%. Regarding short-term risk, MASI is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for MASI.Check AORT's competition here
IRadimed Corporation (NASDAQ: IRMD)
MASI vs IRMD Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while IRMD trades at $86.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas IRMD's P/E ratio is 43.55. In terms of profitability, MASI's ROE is +0.09%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, MASI is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for MASI.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
MASI vs FNA Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas FNA's P/E ratio is -19.83. In terms of profitability, MASI's ROE is +0.09%, compared to FNA's ROE of -0.35%. Regarding short-term risk, MASI is less volatile compared to FNA. This indicates lower risk in terms of short-term price fluctuations for MASI.Check FNA's competition here
Enovis Corporation (NYSE: ENOV)
MASI vs ENOV Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, ENOV has a market cap of 1B. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while ENOV trades at $18.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas ENOV's P/E ratio is 5.20. In terms of profitability, MASI's ROE is +0.09%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, MASI is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for MASI.Check ENOV's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
MASI vs PRCT Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, PRCT has a market cap of 981.9M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while PRCT trades at $17.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas PRCT's P/E ratio is -8.89. In terms of profitability, MASI's ROE is +0.09%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, MASI is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for MASI.Check PRCT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
MASI vs LMRI Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, LMRI has a market cap of 974.7M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while LMRI trades at $10.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas LMRI's P/E ratio is -19.74. In terms of profitability, MASI's ROE is +0.09%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, MASI is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for MASI.Check LMRI's competition here
Bioventus Inc. (NASDAQ: BVS)
MASI vs BVS Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, BVS has a market cap of 949.8M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while BVS trades at $14.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas BVS's P/E ratio is 18.45. In terms of profitability, MASI's ROE is +0.09%, compared to BVS's ROE of +0.28%. Regarding short-term risk, MASI is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for MASI.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
MASI vs CBLL Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, CBLL has a market cap of 930M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while CBLL trades at $24.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas CBLL's P/E ratio is -13.93. In terms of profitability, MASI's ROE is +0.09%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, MASI is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for MASI.Check CBLL's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
MASI vs BBNX Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, BBNX has a market cap of 923.2M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while BBNX trades at $20.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas BBNX's P/E ratio is -12.44. In terms of profitability, MASI's ROE is +0.09%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, MASI is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for MASI.Check BBNX's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
MASI vs CSII Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas CSII's P/E ratio is -20.83. In terms of profitability, MASI's ROE is +0.09%, compared to CSII's ROE of -0.14%. Regarding short-term risk, MASI is less volatile compared to CSII. This indicates lower risk in terms of short-term price fluctuations for MASI.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
MASI vs SIBN Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, SIBN has a market cap of 832M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while SIBN trades at $18.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas SIBN's P/E ratio is -55.18. In terms of profitability, MASI's ROE is +0.09%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, MASI is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for MASI.Check SIBN's competition here
InMode Ltd. (NASDAQ: INMD)
MASI vs INMD Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, INMD has a market cap of 816.5M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while INMD trades at $14.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas INMD's P/E ratio is 9.86. In terms of profitability, MASI's ROE is +0.09%, compared to INMD's ROE of +0.12%. Regarding short-term risk, MASI is less volatile compared to INMD. This indicates lower risk in terms of short-term price fluctuations for MASI.Check INMD's competition here
Varex Imaging Corporation (NASDAQ: VREX)
MASI vs VREX Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, VREX has a market cap of 777.2M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while VREX trades at $18.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas VREX's P/E ratio is 19.43. In terms of profitability, MASI's ROE is +0.09%, compared to VREX's ROE of +0.05%. Regarding short-term risk, MASI is less volatile compared to VREX. This indicates lower risk in terms of short-term price fluctuations for MASI.Check VREX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
MASI vs AHCO Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, AHCO has a market cap of 768.7M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while AHCO trades at $5.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas AHCO's P/E ratio is 11.53. In terms of profitability, MASI's ROE is +0.09%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, MASI is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for MASI.Check AHCO's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
MASI vs AVR Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, AVR has a market cap of 752.6M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while AVR trades at $7.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas AVR's P/E ratio is -3.99. In terms of profitability, MASI's ROE is +0.09%, compared to AVR's ROE of -0.78%. Regarding short-term risk, MASI is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for MASI.Check AVR's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
MASI vs CTKB Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, CTKB has a market cap of 741.3M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while CTKB trades at $5.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas CTKB's P/E ratio is -30.41. In terms of profitability, MASI's ROE is +0.09%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, MASI is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for MASI.Check CTKB's competition here
Surmodics, Inc. (NASDAQ: SRDX)
MASI vs SRDX Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas SRDX's P/E ratio is -34.66. In terms of profitability, MASI's ROE is +0.09%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, MASI is similarly volatile compared to SRDX. This indicates similar risk in terms of short-term price fluctuations for MASI.Check SRDX's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
MASI vs KIDS Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, KIDS has a market cap of 580M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while KIDS trades at $22.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas KIDS's P/E ratio is -19.14. In terms of profitability, MASI's ROE is +0.09%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, MASI is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for MASI.Check KIDS's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
MASI vs APEN Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas APEN's P/E ratio is -9.43. In terms of profitability, MASI's ROE is +0.09%, compared to APEN's ROE of -0.85%. Regarding short-term risk, MASI is less volatile compared to APEN. This indicates lower risk in terms of short-term price fluctuations for MASI.Check APEN's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
MASI vs SSII Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, SSII has a market cap of 578.4M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while SSII trades at $2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas SSII's P/E ratio is -48.17. In terms of profitability, MASI's ROE is +0.09%, compared to SSII's ROE of -0.27%. Regarding short-term risk, MASI is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for MASI.Check SSII's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
MASI vs DCTH Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, DCTH has a market cap of 545.8M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while DCTH trades at $15.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas DCTH's P/E ratio is 1581.00. In terms of profitability, MASI's ROE is +0.09%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, MASI is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for MASI.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
MASI vs ZIMV Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, MASI's ROE is +0.09%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, MASI is similarly volatile compared to ZIMV. This indicates similar risk in terms of short-term price fluctuations for MASI.Check ZIMV's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
MASI vs PACB Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, PACB has a market cap of 531.1M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while PACB trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas PACB's P/E ratio is -4.17. In terms of profitability, MASI's ROE is +0.09%, compared to PACB's ROE of -49.62%. Regarding short-term risk, MASI is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for MASI.Check PACB's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
MASI vs TCMD Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, TCMD has a market cap of 514.7M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while TCMD trades at $22.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas TCMD's P/E ratio is 21.13. In terms of profitability, MASI's ROE is +0.09%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, MASI is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for MASI.Check TCMD's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
MASI vs SGHT Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, SGHT has a market cap of 504.4M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while SGHT trades at $9.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas SGHT's P/E ratio is -16.55. In terms of profitability, MASI's ROE is +0.09%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, MASI is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for MASI.Check SGHT's competition here
Cerus Corporation (NASDAQ: CERS)
MASI vs CERS Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, CERS has a market cap of 493.7M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while CERS trades at $2.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas CERS's P/E ratio is -81.40. In terms of profitability, MASI's ROE is +0.09%, compared to CERS's ROE of -0.10%. Regarding short-term risk, MASI is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for MASI.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
MASI vs NPCE Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, NPCE has a market cap of 482.4M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while NPCE trades at $14.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas NPCE's P/E ratio is -24.82. In terms of profitability, MASI's ROE is +0.09%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, MASI is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for MASI.Check NPCE's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
MASI vs CLPT Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, CLPT has a market cap of 459.1M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while CLPT trades at $15.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas CLPT's P/E ratio is -12.97. In terms of profitability, MASI's ROE is +0.09%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, MASI is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for MASI.Check CLPT's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
MASI vs SENS Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, SENS has a market cap of 411.3M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while SENS trades at $9.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas SENS's P/E ratio is -4.41. In terms of profitability, MASI's ROE is +0.09%, compared to SENS's ROE of -1.66%. Regarding short-term risk, MASI is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for MASI.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
MASI vs OFIX Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, OFIX has a market cap of 397.7M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while OFIX trades at $9.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas OFIX's P/E ratio is -6.41. In terms of profitability, MASI's ROE is +0.09%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, MASI is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for MASI.Check OFIX's competition here
CapsoVision, Inc. (NASDAQ: CV)
MASI vs CV Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, CV has a market cap of 345.7M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while CV trades at $6.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas CV's P/E ratio is -10.98. In terms of profitability, MASI's ROE is +0.09%, compared to CV's ROE of -1.78%. Regarding short-term risk, MASI is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for MASI.Check CV's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
MASI vs SMLR Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas SMLR's P/E ratio is 3.92. In terms of profitability, MASI's ROE is +0.09%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, MASI is similarly volatile compared to SMLR. This indicates similar risk in terms of short-term price fluctuations for MASI.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
MASI vs TMCI Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, TMCI has a market cap of 290.6M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while TMCI trades at $4.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas TMCI's P/E ratio is -4.77. In terms of profitability, MASI's ROE is +0.09%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, MASI is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for MASI.Check TMCI's competition here
Avita Medical Inc. (NASDAQ: RCEL)
MASI vs RCEL Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, RCEL has a market cap of 289.9M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while RCEL trades at $11.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas RCEL's P/E ratio is -8.10. In terms of profitability, MASI's ROE is +0.09%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, MASI is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for MASI.Check RCEL's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
MASI vs CATX Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, CATX has a market cap of 286.3M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while CATX trades at $2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas CATX's P/E ratio is -1.89. In terms of profitability, MASI's ROE is +0.09%, compared to CATX's ROE of -0.42%. Regarding short-term risk, MASI is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for MASI.Check CATX's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
MASI vs TLSI Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, TLSI has a market cap of 270.3M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while TLSI trades at $4.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas TLSI's P/E ratio is -2.61. In terms of profitability, MASI's ROE is +0.09%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, MASI is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for MASI.Check TLSI's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
MASI vs INFU Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, INFU has a market cap of 259.4M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while INFU trades at $12.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas INFU's P/E ratio is 31.35. In terms of profitability, MASI's ROE is +0.09%, compared to INFU's ROE of +0.15%. Regarding short-term risk, MASI is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for MASI.Check INFU's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
MASI vs MGRM Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas MGRM's P/E ratio is -12.00. In terms of profitability, MASI's ROE is +0.09%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, MASI is similarly volatile compared to MGRM. This indicates similar risk in terms of short-term price fluctuations for MASI.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
MASI vs ELMD Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, ELMD has a market cap of 233.3M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while ELMD trades at $28.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas ELMD's P/E ratio is 21.51. In terms of profitability, MASI's ROE is +0.09%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, MASI is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for MASI.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
MASI vs NVRO Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas NVRO's P/E ratio is -1.91. In terms of profitability, MASI's ROE is +0.09%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, MASI is less volatile compared to NVRO. This indicates lower risk in terms of short-term price fluctuations for MASI.Check NVRO's competition here
Profound Medical Corp. (NASDAQ: PROF)
MASI vs PROF Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, PROF has a market cap of 215.1M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while PROF trades at $5.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas PROF's P/E ratio is -6.04. In terms of profitability, MASI's ROE is +0.09%, compared to PROF's ROE of -0.56%. Regarding short-term risk, MASI is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for MASI.Check PROF's competition here
RxSight, Inc. (NASDAQ: RXST)
MASI vs RXST Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, RXST has a market cap of 193.3M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while RXST trades at $4.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas RXST's P/E ratio is -4.13. In terms of profitability, MASI's ROE is +0.09%, compared to RXST's ROE of -0.17%. Regarding short-term risk, MASI is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for MASI.Check RXST's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
MASI vs BSGM Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas BSGM's P/E ratio is -5.81. In terms of profitability, MASI's ROE is +0.09%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, MASI is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for MASI.Check BSGM's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
MASI vs MDGS Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas MDGS's P/E ratio is -0.27. In terms of profitability, MASI's ROE is +0.09%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, MASI is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for MASI.Check MDGS's competition here
Neuronetics, Inc. (NASDAQ: STIM)
MASI vs STIM Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, STIM has a market cap of 177.8M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while STIM trades at $2.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas STIM's P/E ratio is -5.81. In terms of profitability, MASI's ROE is +0.09%, compared to STIM's ROE of -1.51%. Regarding short-term risk, MASI is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for MASI.Check STIM's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
MASI vs FOCL Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, FOCL has a market cap of 169.8M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while FOCL trades at $4.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas FOCL's P/E ratio is -4.38. In terms of profitability, MASI's ROE is +0.09%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, MASI is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for MASI.Check FOCL's competition here
Quanterix Corporation (NASDAQ: QTRX)
MASI vs QTRX Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, QTRX has a market cap of 165.8M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while QTRX trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas QTRX's P/E ratio is -1.39. In terms of profitability, MASI's ROE is +0.09%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, MASI is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for MASI.Check QTRX's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
MASI vs QIPT Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas QIPT's P/E ratio is -15.87. In terms of profitability, MASI's ROE is +0.09%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, MASI is similarly volatile compared to QIPT. This indicates similar risk in terms of short-term price fluctuations for MASI.Check QIPT's competition here
Quantum-Si incorporated (NASDAQ: QSI)
MASI vs QSI Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, QSI has a market cap of 157.3M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while QSI trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas QSI's P/E ratio is -1.73. In terms of profitability, MASI's ROE is +0.09%, compared to QSI's ROE of -0.47%. Regarding short-term risk, MASI is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for MASI.Check QSI's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
MASI vs LUCD Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, LUCD has a market cap of 153.7M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while LUCD trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas LUCD's P/E ratio is -2.18. In terms of profitability, MASI's ROE is +0.09%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, MASI is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for MASI.Check LUCD's competition here
Inogen, Inc. (NASDAQ: INGN)
MASI vs INGN Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, INGN has a market cap of 147.3M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while INGN trades at $5.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas INGN's P/E ratio is -5.98. In terms of profitability, MASI's ROE is +0.09%, compared to INGN's ROE of -0.13%. Regarding short-term risk, MASI is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for MASI.Check INGN's competition here
iCAD, Inc. (NASDAQ: ICAD)
MASI vs ICAD Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas ICAD's P/E ratio is -20.37. In terms of profitability, MASI's ROE is +0.09%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, MASI is similarly volatile compared to ICAD. This indicates similar risk in terms of short-term price fluctuations for MASI.Check ICAD's competition here
electroCore, Inc. (NASDAQ: ECOR)
MASI vs ECOR Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, ECOR has a market cap of 99.4M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while ECOR trades at $11.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas ECOR's P/E ratio is -6.57. In terms of profitability, MASI's ROE is +0.09%, compared to ECOR's ROE of +5.25%. Regarding short-term risk, MASI is less volatile compared to ECOR. This indicates lower risk in terms of short-term price fluctuations for MASI.Check ECOR's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
MASI vs HJLI Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas HJLI's P/E ratio is N/A. In terms of profitability, MASI's ROE is +0.09%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, MASI is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for MASI.Check HJLI's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
MASI vs ASXC Comparison September 2026
Masimo Corporation (NASDAQ: MASI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MASI stands at 9.4B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, MASI is priced at $179.95 on the NASDAQ, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MASI currently has a P/E ratio of 44.43, whereas ASXC's P/E ratio is -1.12. In terms of profitability, MASI's ROE is +0.09%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, MASI is less volatile compared to ASXC. This indicates lower risk in terms of short-term price fluctuations for MASI.Check ASXC's competition here